相关实验视频

Updated: Jun 17, 2025

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

过去和现在:关于治疗复发性卵巢癌的文献计量研究

Xiao-Yuan Hao¹, Wen-Wei Song^2,3, Miao-Ling Li¹

¹Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.

Frontiers in pharmacology

|August 14, 2024

概括

这种文献计量分析揭示了复发性卵巢癌 (ROC) 治疗的研究趋势日益增加. 维护疗法,包括血管生成抑制剂和PARP抑制剂,正在成为ROC化疗的关键补充剂.

科学领域:

妇科瘤学妇科瘤学
医学恶性疾病研究研究
图书统计分析图书统计分析

背景情况:

卵巢癌 (OC) 的全球死亡率很高,主要是由于其复发性.
最近的趋势显示,OC死亡率下降,归因于新的治疗进展.
在复发性OC (ROC) 治疗中缺乏对新药应用的可视化分析.

研究的目的:

对复发性卵巢癌 (ROC) 的不断发展的治疗模式进行文献分析.
确定ROC治疗中的关键研究趋势,有影响力的贡献者和新兴的治疗策略.

主要方法:

从MEDLINE和科学网络核心集合 (WOSCC) 中系统地收集ROC治疗文件.
使用微软Excel,CiteSpace和VOSviewer进行数据分析.
分析包括出版趋势,国家/机构/作者贡献,共同引用网络和关键字的共同出现.

主要成果:

观察到ROC治疗出版物的上升趋势.
美国领导了贡献,德克萨斯大学系统是最具生产力的机构.
关键的研究领域包括基于的药物,帕克利塔塞尔,血管生成抑制剂 (AIs),免疫检查点抑制剂 (ICIs) 和多 (ADP-ribose) 聚合酶抑制剂 (PARPis).

结论:

国际合作推动了ROC治疗研究的进展.
研究热点集中在领先的妇科瘤学期刊上.
使用AI或PARPis的维持疗法是ROC基化疗的重要补充.

关键词:

血管新生抑制剂血管新生抑制剂文献计量分析的分析基于的化学疗法.聚 (ADP-ribose) 聚合酶抑制剂的使用.再发性卵巢癌的发生.

更多相关视频

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...